Given more sophisticated methods to administer drugs and manage side effects of therapy in humans, we anticipate that patients with ovarian cancer could be treated with an inhibitor of CXCL12-CXCR4 and cisplatin for longer periods of time. The gene discussed is CXCL12; the disease is ovarian cancer.